39.40

0.81% 0.315

After Hours: 39.40

Revolution Medicines Inc (RVMD)

Overview News Price History Option Chain Financials Why RVMD Down? Discussions Forecast

Revolution Medicines Inc stock is traded at $39.40, with a volume of 2.62M. It is up +0.81% in the last 24 hours and down -3.12% over the past month. Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.

Previous Close:

$39.09

Open:

$38.92

24h Volume:

2.62M

Relative Volume:

1.46

Market Cap:

$7.34B

Revenue:

$29.52M

Net Income/Loss:

$-567.06M

P/E Ratio:

-10.77

EPS:

-3.66

Net Cash Flow:

$-551.11M

1W Performance:

-0.93%

1M Performance:

-3.12%

6M Performance:

-31.89%

1Y Performance:

+3.22%

1-Day Range:

$37.95

$40.19

1-Week Range:

$36.53

$40.19

52-Week Range:

$29.17

$62.40

Revolution Medicines Inc Stock (RVMD) Company Profile

Name

Revolution Medicines Inc

Sector

Healthcare (1170)

Industry

Biotechnology (667)

Phone

415-766-3638

Address

700 SAGINAW DR, REDWOOD CITY, CA

Employee

616

Twitter

Next Earnings Date

2024-11-06

Latest SEC Filings

RVMD's Discussions on Twitter

Compare RVMD with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RVMD Revolution Medicines Inc	39.40	7.41B	29.52M	-567.06M	-551.11M	-3.66
ONC Beone Medicines Ltd Adr	245.58	26.10B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	442.05	111.96B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.35	42.96M	0	0	0	0.00
VRNA Verona Pharma Plc Adr	81.20	6.39B	0	-153.72M	-103.81M	-2.00
REGN Regeneron Pharmaceuticals Inc	490.28	63.52B	14.09B	4.50B	2.96B	39.28

Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-16-24	Reiterated	Needham	Buy
Jul-12-24	Initiated	Barclays	Overweight
Jul-08-24	Initiated	Jefferies	Buy
Apr-12-24	Reiterated	Needham	Buy
Apr-10-24	Upgrade	Raymond James	Outperform → Strong Buy
Mar-11-24	Initiated	Piper Sandler	Overweight
Jan-05-24	Upgrade	BofA Securities	Neutral → Buy
Jan-04-24	Initiated	Wedbush	Outperform
Nov-16-23	Initiated	Raymond James	Outperform
Feb-28-23	Upgrade	JP Morgan	Neutral → Overweight
Dec-14-22	Initiated	Needham	Buy
Oct-21-22	Initiated	Oppenheimer	Outperform
May-20-22	Initiated	BofA Securities	Neutral
Mar-01-22	Upgrade	Stifel	Hold → Buy
Sep-23-21	Initiated	Stifel	Hold
Aug-12-21	Downgrade	Goldman	Buy → Neutral
May-18-21	Initiated	Goldman	Buy
May-21-20	Initiated	H.C. Wainwright	Buy
Mar-09-20	Initiated	Cowen	Outperform
Mar-09-20	Initiated	Guggenheim	Buy
Mar-09-20	Initiated	JP Morgan	Neutral

View All

Revolution Medicines Inc Stock (RVMD) Latest News

May 27, 2025

rEvolution Appoints Brian Gabriel as Vice President of Marketing Communications - GlobeNewswire Inc.

May 27, 2025

May 26, 2025

Revolution Medicines’ SWOT analysis: stock shows promise amid clinical progress - Investing.com Nigeria

May 26, 2025

May 24, 2025

(RVMD) On The My Stocks Page - news.stocktradersdaily.com

May 24, 2025

May 15, 2025

First subject dosed in Revolution Medicines’ Phase III NSCLC treatment trial - Yahoo Finance

May 15, 2025

Revolution Medicines begins phase 3 trial for lung cancer drug By Investing.com - Investing.com Canada

May 15, 2025

Revolution Medicines Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating Daraxonrasib in Previously Treated Patients with RAS Mutant Non-Small Cell Lung Cancer - BioSpace

May 15, 2025

May 14, 2025

Revolution Medicines price target lowered to $72 from $73 at H.C. Wainwright - TipRanks

May 14, 2025

May 12, 2025

Revolution medicines outlines 2025 focus on RAS(ON) inhibitors in key cancer trials - MSN

May 12, 2025

Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights - Yahoo Finance

May 12, 2025

May 10, 2025

We Think Revolution Medicines (NASDAQ:RVMD) Can Afford To Drive Business Growth - Yahoo Finance

May 10, 2025

May 09, 2025

Revolution’s KRAS drugs appear competitive in several lung cancer settings - Endpoints News

May 09, 2025

May 08, 2025

Revolution Medicines’ Earnings Call: Optimism Amid Rising Costs - TipRanks

May 08, 2025

RVMD: Guggenheim Maintains Buy Rating, Lowers Price Target to $8 - GuruFocus

May 08, 2025

The Lustgarten Foundation Honors Revolution Medicines for Transformative Research in Pancreatic Cancer - PRWeb

May 08, 2025

Oppenheimer Raises Price Target for RVMD, Maintains Outperform R - GuruFocus

May 08, 2025

RVMD Price Target Lowered but Buy Rating Maintained by Guggenheim | RVMD Stock News - GuruFocus

May 08, 2025

Revolution Medicines (RVMD) Target Price Raised Amid Positive Ou - GuruFocus

May 08, 2025

Revolution Medicines (RVMD) Target Price Raised Amid Positive Outlook | RVMD Stock News - GuruFocus

May 08, 2025

Needham Reiterates Buy Rating for Revolution Medicines (RVMD) | RVMD Stock News - GuruFocus

May 08, 2025